(MENAFN- Baystreet) 11:27 AM EST - Oncolytics Biotech Inc: Announced the formation of its Gastrointestinal Tumor Scientific Advisory Board (SAB), a group of leading oncology experts assembled to guide the Company’s clinical and regulatory strategy for developing pelareorep as a treatment for GI cancers. Oncolytics Biotech Inc
shares N are trading ** off $0.10** at $0.99.
Full Press Release:
MENAFN04112025000212011056ID1110295309
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 11:27 AM EST - Oncolytics Biotech Inc: Announced the formation of its Gastrointestinal Tumor Scientific Advisory Board (SAB), a group of leading oncology experts assembled to guide the Company’s clinical and regulatory strategy for developing pelareorep as a treatment for GI cancers. Oncolytics Biotech Inc shares N are trading ** off $0.10** at $0.99.
Full Press Release:
MENAFN04112025000212011056ID1110295309